Can your genes guide better depression treatment? new trial aims to find out.

NCT ID NCT07373470

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study will test whether having a pharmacist review a patient's genetic test results can improve treatment for major depression. 220 adults in Pennsylvania who are starting or changing antidepressant medication will be randomly assigned to either receive this specialized medication management or usual care. The goal is to see if the genetic-guided approach leads to better control of depression symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pharmacogenomic (PGx) testing and comprehensive medication management
What this could lead to
If successful, this could show that using genetic information to guide antidepressant choices leads to better symptom relief and fewer side effects.
What could go wrong
This is a relatively small, early-stage trial (220 participants) and the benefit of genetic testing for depression is still unproven. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY PHARMACY SERVICES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.